American College of Cardiology, March 16-18
Physician's Briefing,
The American College of Cardiology's 68th Annual Scientific Session and Expo The annual meeting of the American College of…
The American College of Cardiology's 68th Annual Scientific Session and Expo The annual meeting of the American College of…
Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the…
, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for…
, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for…
, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada -approved medication for…
There have been a number of major developments in the field of cardiology in 2019.
December 16, 2019 — The U.S. Food and Drug Administration (FDA) Dec. 13, approved the use of Vascepa (icosapent ethyl) capsules…
Share on Pinterest One prescription-strength fish oil can be equal to 10 to 40 capsules of over-the-counter fish oil.
Statin + Eicosapentaenoic acid = cardiovascular health. Credit:, BioSerendipity Clinical trials shows that statins plus a high…
Until now, there has been very little guidance about what dose of EPA and DHA should be tested in a study.
A new study published in the American Journal of Clinical Nutrition will make it possible for researchers to calculate how much…
.newsblock { width: 200px; height:200px; float:right; padding-left:15px; padding-right:15px; } A new study published in the…
Meeting Coverage of 2019 Updated ADA Standards of Medical Care in Diabetes to Include Role of Icosapent Ethyl as a Management…
Meeting Coverage of 2019 Updated ADA Standards of Medical Care in Diabetes to Include Role of Icosapent Ethyl as a Management…
Meeting Coverage of 2019 Updated ADA Standards of Medical Care in Diabetes to Include Role of Icosapent Ethyl as a Management…
— Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has been…
, four months sooner than expected - Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular…
- Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed…
, four months sooner than expected - Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular…
sNDA Based on Landmark REDUCE-IT TrialIn REDUCE-IT, Vascepa achieved the primary endpoint with a 25% relative risk reduction…
, four months sooner than expected - Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular…
- Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed…
, four months sooner than expected - Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular…
Vascepa’s REDUCE-IT Trial Impact on Clinical Practice an Important Highlight BEDMINSTER, N.J.
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
Vascepa's REDUCE-IT Trial Impact on Clinical Practice an Important Highlight BEDMINSTER, N.J.
(GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at…
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year BEDMINSTER, N.J., and DUBLIN, Ireland…
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today…
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at…
NEW ORLEANS – The success of icosapent ethyl in cutting triglyceride levels and reducing cardiovascular disease events in at-risk…
New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
Amarin has submitted a supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) to reduce the risk of major…
— Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic events…
NEW ORLEANS — A new analysis of the REDUCE-IT trial has shown that in addition to a large reduction in first ischemic events…
March 29, 2019 — Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total…
New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with…
Icosapent ethyl (Vascepa—Amarin) may be more effective in preventing ischemic events than previously reported.
Icosapent ethyl (Vascepa—Amarin) may be more effective in preventing ischemic events than previously reported.
meeting of the American College of Cardiology was held from March 16 to 18 in New Orleans and attracted more than 20,000…
The American College of Cardiology's 68th Annual Scientific Session and Expo The annual meeting of the American College of…
The American College of Cardiology's 68th Annual Scientific Session and Expo The annual meeting of the American College of…
(HealthDay News) -- For statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
-- For statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes, icosapent ethyl…
Anti-Oxidant Effects of Eicosapentaenoic Acid Data at Pharmacologic Concentrations Also Presented BEDMINSTER, N.J., and DUBLIN…
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa…
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa…
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa…
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology's 68th…
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(CNN) -- New numbers suggest that a purified fish oil derivative, a prescription drug called Vascepa, is more effective at…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
NEW ORLEANS -- A prescription-grade fish oil was able to prevent multiple cardiovascular events, not just first events…
NEW ORLEANS — Icosapent ethyl, a pharmaceutical-grade omega-3 fatty acid, was in the spotlight again at the American College of…
(CNN) New numbers suggest that a purified fish oil derivative, a prescription drug called Vascepa, is more effective at…
Deepak L. Bhatt NEW ORLEANS — Icosapent ethyl, a pharmaceutical-grade omega-3 fatty acid, was in the spotlight again at the…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription…
/PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of…
/PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of…
PR Newswire BEDMINSTER, N.J. and DUBLIN, March 18, 2019 BEDMINSTER, N.J. and DUBLIN, March 18, 2019 /PRNewswire/ -- Amarin…
/PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of…
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied BEDMINSTER, N.J.
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa…
/PRNewswire/ -- Amarin Corporation PLC (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of…